Centenary Institute researcher Dr Jaesung Peter Choi has been awarded “The FEBS Journal Poster Prize” at the 14th Annual Angioma Alliance CCM Scientific Meeting, held in Washington DC. The prize recognises the best poster presentation by a trainee.
Dr Choi was able to attend the meeting after receiving the Australian Vascular Biology Society (AVBS) Travel Award.
He was joined by Head of Centenary’s Cell Signalling Laboratory, Dr Xiangjian (XJ) Zheng.
The pair presented their most recent study, published in the scientific journal Science Advances, which identified a cancer drug as a potential treatment option for Cerebral Cavernous Malformations (CCM) – a leading cause of stroke in young people.
A study led by researchers at the Centenary Institute has identified a drug currently used to treat cancer patients, as a potential treatment option for a leading cause of stroke in young people.
Cerebral Cavernous Malformations (CCM) occurs when abnormal and dilated thin-walled blood vessels form clusters in the brain; altering blood flow. The condition affects as many as 1-in-200 people, and can cause bleeding, epilepsy and stroke.
Currently, the only treatment for CCM is surgery, which is not always possible; highlighting the urgent need for non-invasive, pharmacological treatment options.
Metaflammation is a new term that refers to low levels of inflammation throughout the body.
Your body use the essential repair process of inflammation to heal the body. When you have a full blown infection your levels are very high. Metaflammation is different. It is much much lower but constant.
This new aspect of inflammation has come to light, its connection with chronic metabolic diseases, like obesity and diabetes. One of the reasons this link is really important is that we are able to control with small molecule or biological therapeutics some aspects of inflammation. This approach might become really useful in treating some diseases that were thought to be diet or environment influenced and may become a devastating problem in the future.
Inflammation research: why it matters
A third of all diabetics will suffer from vision loss and potential blindness during their lifetime. This condition is caused by inflammation in the retina blood vessels.
We have developed an exciting new drug which has the potential to mend the damaged blood vessels and prevent loss of sight.